Table 2 Adherence in men receiving FDC and concomitant therapy with an α-blocker plus an antimuscarinic
FDC α-blocker and antimuscarinic | Concomitant therapy | ||
|---|---|---|---|
α-blocker | antimuscarinic | ||
MPR-fixed | |||
N | 566 | 726 | 726 |
Mean (SD) | 0.91 (0.52) | 0.95 (0.37) | 0.89 (0.31) |
Adherent,a n (%) | 453 (80.0) | 623 (85.8) | 546 (75.2) |
MPR-variable | |||
N | 566 | 726 | 726 |
Mean (SD) | 0.67 (0.31) | 0.69 (0.34) | 0.64 (0.32) |
Adherent,a n (%) | 275 (48.6) | 358 (49.3) | 319 (43.9) |
MPR-fixed (persistent men only) | |||
N | 313 | 380 | 380 |
Mean (SD) | 0.83 (0.21) | 0.93 (0.22) | 0.85 (0.22) |
Adherent,a n (%) | 235 (75.1) | 324 (85.3) | 282 (74.2) |